MontalbanXHemmerBRammohanK. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis: Results of the Phase III double-blind, placebo-controlled ORATORIO study. Neurology2016; 86: S49.001.
3.
KapposLBar-OrACreeB. Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, doubleblind, Phase III EXPAND study. In: Proceedings of the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), London, 14–17 September 2016.
4.
OntanedaDFoxRChatawayJ.Clinical trials in progressive multiple sclerosis: Lessons learned and future perspectives. Lancet Neurol2015; 14: 208–223.
5.
TourbahALebrunCEganG. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo controlled study. Mult Scler2016; 22: 1719–1731.
